The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was $1.66 for the day, up 1.22% from the previous closing price of $1.64. In other words, the price has increased by $1.22 from its previous closing price. On the day, 2.51 million shares were traded. LXRX stock price reached its highest trading level at $1.72 during the session, while it also had its lowest trading level at $1.61.
Ratios:
Our analysis of LXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.49 and its Current Ratio is at 11.51. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.
On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.Jefferies initiated its Hold rating on March 07, 2023, with a $3 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.
COATS LONNEL bought 90,000 shares of LXRX for $94,797 on Nov 16 ’23. The Chief Executive Officer now owns 914,359 shares after completing the transaction at $1.05 per share. On Nov 10 ’23, another insider, COATS LONNEL, who serves as the Chief Executive Officer of the company, bought 10,000 shares for $1.01 each. As a result, the insider paid 10,100 and bolstered with 824,359 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 600076736 and an Enterprise Value of 395803200. For the stock, the TTM Price-to-Sale (P/S) ratio is 164.86 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 108.707 whereas that against EBITDA is -2.015.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -10.42%, while the 200-Day Moving Average is calculated to be -7.44%.
Shares Statistics:
LXRX traded an average of 2.82M shares per day over the past three months and 2683410 shares per day over the past ten days. A total of 361.49M shares are outstanding, with a floating share count of 349.01M. Insiders hold about 2.81% of the company’s shares, while institutions hold 76.85% stake in the company. Shares short for LXRX as of 1722384000 were 22350800 with a Short Ratio of 7.93, compared to 1719532800 on 20197013. Therefore, it implies a Short% of Shares Outstanding of 22350800 and a Short% of Float of 13.71.
